Mainz Biomed (QUCY) Stock Price, News & Analysis

Company Overview

Mainz Biomed is a molecular diagnostics company focused on developing non-invasive tests for the early detection of cancer. The company’s technology uses molecular biomarkers and multiplex polymerase chain reaction (PCR) analysis to identify disease-related signals in patient samples.

Its principal product is ColoAlert, a stool-based screening test designed to detect colorectal cancer and advanced adenomas. The test analyzes stool samples for specific genetic mutations and blood-related markers associated with colorectal disease, offering an alternative to more invasive screening procedures such as colonoscopy.

Founded in 2016 and headquartered in Germany, Mainz Biomed has commercialized ColoAlert in Germany and other European markets and has pursued regulatory authorization and clinical development activities in the United States. The company has also conducted studies and collaborations intended to evaluate the test’s performance and support broader adoption of molecular colorectal cancer screening.

Key Stats

• Today's Range: $1.29 to $1.34
• 50-Day Range: $1.06 to $1.60
• 52-Week Range: $0.30 to $4.93
• Volume: 253,258 shs
• Average Volume: 705,023 shs
• Market Capitalization: $19.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Mainz Biomed Stock Analysis - MarketRank™

Mainz Biomed scored higher than 35% of companies evaluated by MarketBeat, and ranked 579th out of 668 stocks in the industrials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Hold

Consensus Rating

Mainz Biomed has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 strong buy rating, no buy ratings, 2 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Mainz Biomed has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mainz Biomed are expected to grow in the coming year, from ($0.49) to ($0.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mainz Biomed is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mainz Biomed is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mainz Biomed has a P/B Ratio of 19.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

13.12% of the float of Mainz Biomed has been sold short.

Short Interest Ratio / Days to Cover

Mainz Biomed has a short interest ratio ("days to cover") of 2.07, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mainz Biomed has recently decreased by 17.06%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mainz Biomed does not currently pay a dividend.

Dividend Growth

Mainz Biomed does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: N/A

News Sentiment

Mainz Biomed has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Industrials companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Mainz Biomed this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for QUCY on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

3 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mainz Biomed insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.10% of the stock of Mainz Biomed is held by insiders.

Percentage Held by Institutions

Mainz Biomed has minimal institutional ownership at this time.

Company Calendar

• Today: 9/25/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Industrials
• Industry: Aerospace & Defense
• Sub-Industry: Aerospace & Defense
• Current Symbol: NASDAQ:QUCY
• CIK: 1874252
• Web: quantum-cyber.ai
• Phone: 49 6131 5542860
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.56
• Quick Ratio: 5.56

Sales & Book Value

• Annual Sales: $540 thousand
• Price / Sales: 36.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.07 per share
• Price / Book: 19.00

Miscellaneous

• Outstanding Shares: 14,660,000
• Free Float: 14,207,000
• Market Cap: $19.50 million
• Optionable: N/A
• Beta: 2.35